Thread by @MGinvestor

Portfolio Update:
THREAD 1/n
Just to recap for new followers. I have been investing on and off since 2001. More serious since 2006. You may have noticed I’ve been generally quiet about my trades over the last few months. Was waiting for opportunities from my WL some of which

2/n I’ve taken. I’ve already mentioned most of these shares with some rationale in the past so I’ll mention why for others now. My portfolio as it stands in order of position size:
BVXP (16.4%) – first bought in July 2016. Initial position up 330%.

3/n WATR (11.6%) – Rebought in Dec 2016 and initial position up 229%. FYI had to take part in placing to get to such a meaningful position size.
ABDP (9.4%) – first bought in summer 2015. Initial position up 760%. Top sliced in 2017 as position became way too big but still

4/n happy to continue to hold after topping up in Oct 2018.
TRCS (7.9%) - Bought in Nov 2018 up 8.8%.
FLTA (6.4%) – first bought in June 2017. Initial position up 113%. The Acquisition hasn’t really been factored into the share price so that will be a catalyst IMHO.

5/n SDI (6.1%) – Bought in Dec 2018 up 37% FYI took part in placing in Feb 2019.
AIEA (4.3%) - Bought in Dec 2018 up 30%. Speak to @rhomboid1MF if you have any Q’s 😉
The below shares are probably what some of you are going to be interested in 😉

6/n EUSP (4.1%) -Rebought end March 2019 up 0%. Feel the price at this level offers good risk/reward. For £6.7m mcap you have: possible inflection point? Profitable, sticky rev has been growing consistently 70% recurring, part of framework agreements. CEO founder holds sig amount

7/n FIPP (3.9%) – Rebought in March/April 2019 up 0%. Was a mistake selling out in Oct 2017 and after reviewing my notes and latest news feel they are in a much better situation. Mcap of £35m is covered by their 3.3% stake in Exscientia. Worth chewing over that...

8/n ...They’ve already told us in March that FY results will be ahead but share price hasn’t moved. Worth researching their holdings Pulsiv, Alusid, Fieldwork Robotics, Vaccine Group, Molendotech. CEO holds sig amount, salaries reasonable. Operates differently to typical VC

9/n LSAI (2.2%) – Warning PUNT! Been buying scraps since their TS avg price 2.42p. Up 3%. High risk/high reward. This has been completely revamped from the previous disaster that used to be called Proxama. New management, new business strategy. Overheads have been reduced...

10/n ...significantly & they are developing & promoting their Verify product. If they achieve their KPI’s this year it will have a good catalyst. They are trying to get into the US market so we’ll have to wait & see how that progresses. Plenty of info available online

11/n PTRO (2.1%) Warning PUNT! High risk/high reward. Had been on WL since listing and been studying carefully. I think I understand(!) CEO Subesh to some level. What he achieved with his previous company Subex was quite impressive and a fraction of that success here would do...

12/END ...wonders for the share price. When his brother sold out I took the opportunity to buy. Avg price paid 84p so up 0%. They have announced some decent contracts.
Cash at ~25% but bear in mind I’ve added more cash recently so its skewed.

Any questions fire away.